Abivax (ABVX) Income from Continuing Operations (2022 - 2026)
Abivax (ABVX) posted quarterly Income from Continuing Operations of 56209840.15 for Q1 2026, down 2.04% year-over-year from 57379202.42 in Q1 2025, and up 31.37% quarter-over-quarter from 81899773.61 in Q4 2025.
Abivax (ABVX) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Abivax's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 56209840.15 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 2.04% year-over-year to 56209840.15; the TTM figure through Mar 2026 stood at 372196260.79 (down 86.54% YoY), while the FY2025 annual figure was 377732120.52, down 100.62% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 56209840.15, up from 81899773.61 in the prior quarter.
- The five-year high for Income from Continuing Operations was 41750931.33 in Q2 2024, with the low at 179283950.7 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 56209840.15 (2026), against an average of 74679623.72.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 69.33% in 2024, then sank 195.6% in 2025.
- Abivax's Income from Continuing Operations stood at 66112029.27 in 2022, then plunged by 107.34% to 137074744.4 in 2023, then surged by 69.33% to 42034268.66 in 2024, then slumped by 94.84% to 81899773.61 in 2025, then soared by 31.37% to 56209840.15 in 2026.
- Business Quant data shows ABVX's Income from Continuing Operations at 56209840.15 in Q1 2026, 81899773.61 in Q4 2025, and 179283950.7 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | -56.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.21 Mn |
| Dec 31, 2025 | -81.90 Mn |
| Sep 30, 2025 | -179.28 Mn |
| Jun 30, 2025 | -54.80 Mn |
| Mar 31, 2025 | -55.09 Mn |
| Dec 31, 2024 | -42.03 Mn |
| Sep 30, 2024 | -60.65 Mn |
| Jun 30, 2024 | -41.75 Mn |
| Mar 31, 2024 | -46.57 Mn |
| Dec 31, 2023 | -137.07 Mn |
| Dec 31, 2022 | -66.11 Mn |